133406-29-8
133406-29-8 结构式
基本信息
6-氯-2-(三氯甲基)-4H-苯并吡喃-4-酮
ST034307 >=98% (HPLC)
ST034307
ST-034307
ST 034307
6-chloro-2-(trichloromethyl)-4H-chromen-4-one
6-Chloro-2-(trichloromethyl)-4H-1-benzopyran-4-one
4H-1-Benzopyran-4-one, 6-chloro-2-(trichloromethyl)-
物理化学性质
| 报价日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
| 2024/04/30 | HY-101279 | 133406-29-8 ST034307 | 133406-29-8 | 5mg | 770元 |
| 2024/04/30 | HY-101279 | 133406-29-8 ST034307 | 133406-29-8 | 10mM * 1mLin DMSO | 847元 |
| 2024/04/30 | HY-101279 | 133406-29-8 ST034307 | 133406-29-8 | 10mg | 1200元 |
常见问题列表
IC50: 2.3 μM (AC1)
ST034307 reveals selective inhibition of AC1 and potentiates AC8 activity to a nonsignificant small extent. ST034307 potentiates phorbol 12-myristate 13-acetate (PMA)-stimulated cAMP production by AC2. ST034307 significantly inhibits the forskolin- or isoproterenol-stimulated AC1 activity in HEK cells stably expressing AC1. In contrast, ST034307 has no significant effects in the wild-type HEK cells. ST034307 significantly inhibits the Ca 2+ /calmodulin-stimulated cAMP accumulation in the hippocampal homogenates. ST034307 dose-dependently inhibits both the development and the maintenance of MOR-mediated sensitization of AC1.
ST034307 (0.25 μg) causes a significant relief of CFA-induced inflammatory pain in mice. ST034307 exhibits an estimated median effective dose (E 50 ) value for analgesia of 0.28 μg in the mouse pain model.